This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

This study has been terminated.
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: May 17, 2012
Last updated: September 23, 2015
Last verified: September 2015
The purpose of this study is to determine whether BMS-823778 is safe and effective in the treatment of hypertension in overweight and obese patients.

Condition Intervention Phase
Hypertension Drug: BMS-823778 Drug: Placebo matching with BMS-823778 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2B Trial to Evaluate the Safety and Efficacy of BMS-823778 in Overweight and Obese Subjects With Inadequately Controlled Hypertension

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • The dose-dependent trend among doses of BMS-823778 and placebo by assessing the change from baseline in 24-hour ambulatory diastolic blood pressure following 12 weeks of double-blind treatment [ Time Frame: At Day -7 (baseline) and Week 12 ]

Secondary Outcome Measures:
  • Change in 24-hour ambulatory systolic blood pressure (SBP)(evaluation of the dose-dependent trend) [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in 24-hour ambulatory diastolic blood pressure (DBP) [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in 24-hour ambulatory SBP [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in ambulatory daytime and nighttime DBP [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in ambulatory daytime and nighttime SBP [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in seated DBP [ Time Frame: At Day -7 (baseline) and Week 12 ]
  • Change in seated SBP [ Time Frame: At Day -7 (baseline) and Week 12 ]

Enrollment: 7
Study Start Date: July 2012
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1: BMS-823778 (2mg) Drug: BMS-823778
Capsules, Oral, 2 mg, Once daily, 12 weeks
Experimental: Arm2: BMS-823778 (6mg) Drug: BMS-823778
Capsules, Oral, 6 mg, Once daily, 12 weeks
Experimental: Arm 3: BMS-823778 (15mg) Drug: BMS-823778
Capsules, Oral, 15 mg, Once daily, 12 weeks
Experimental: Arm4: Placebo Drug: Placebo matching with BMS-823778
Capsules, Oral, 0 mg, Once daily, 12 weeks


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Qualifying seated blood pressure between ≥90 and ≤105 mmHg diastolic AND ≤155 mmHg systolic
  • Mean 24-hour diastolic blood pressure ≥85 mmHg
  • Body mass index (BMI) ≥27 kg/m2
  • If receiving an oral anti-hyperglycemic medication or a cholesterol lowering medication, receiving a stable dose for at least 6 weeks

Exclusion Criteria:

  • History of Cushing's disease or syndrome, or Addison's disease
  • Glycosylated hemoglobin (HbA1c) ≥10%
  • Cerebrovascular insult, unstable angina, or myocardial infarction (MI) within 6 months
  • History of impaired renal or hepatic function
  • BMI ≥50 kg/m2
  • Any injectable antihyperglycemic agent (such as insulin) within 16 weeks
  • Currently receiving more than one class of antihypertensive agents within 4 weeks
  • Daily use of nonsteroidal anti-inflammatory agents within 1 week
  • Use of androgen medications, including topical preparations, within 6 weeks
  • Diagnosis or history of breast cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01602367

  Hide Study Locations
United States, Arkansas
Nea Baptist Clinic
Jonesboro, Arkansas, United States, 72401
United States, California
Local Institution
Los Angeles, California, United States, 90057
Desert Medical Group Inc.
Palm Springs, California, United States, 92262
United States, Florida
Local Institution
Coral Gables, Florida, United States, 33134
United States, Georgia
Local Institution
Atlanta, Georgia, United States, 30303
United States, Louisiana
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States, 70808-4124
Local Institution
New Orleans, Louisiana, United States, 70115
United States, New Jersey
Anderson And Collins Clinical Research, Inc.
Edison, New Jersey, United States, 08817
Premier Research
Trenton, New Jersey, United States, 08611
United States, New York
Syracuse Preventive Cardiology
Syracuse, New York, United States, 13202-3108
United States, North Carolina
Metrolina Internal Medicine
Charlotte, North Carolina, United States, 28204
Pharmquest, Llc
Greensboro, North Carolina, United States, 27408
Pmg Research Of Salisbury
Salisbury, North Carolina, United States, 28144
Local Institution
Shelby, North Carolina, United States, 28150
Local Institution
Shelby, North Carolina, United States, 28152
Local Institution
Winston-salem, North Carolina, United States, 27103
United States, Ohio
Sterling Research Grp, Ltd.
Cincinnati, Ohio, United States, 45246
United States, South Carolina
Local Institution
Greenville, South Carolina, United States, 29615
United States, Utah
Local Institution
Layton, Utah, United States, 84041
United States, Virginia
Manassas Clinical Research Center
Manassas, Virginia, United States, 20110
National Clinical Research - Norfolk, Inc.
Norfolk, Virginia, United States, 23502
National Clinical Research - Richmond, Inc.
Richmond, Virginia, United States, 23294
Local Institution
Barranquilla, Colombia
Local Institution
Bucaramanga, Colombia
Local Institution
Cartagena, Colombia
Local Institution
Manizales, Colombia
Local Institution
Medellin, Colombia
Local Institution
Balatonfured, Hungary, H-8230
Local Institution
Budapest, Hungary, 1125
Local Institution
Budapest, Hungary, 1133
Local Institution
Budapest, Hungary, 1134
Local Institution
Debrecen, Hungary, 4026
Puerto Rico
Local Institution
Ponce, Puerto Rico, 00717
Local Institution
Odeshog, Sweden, 599 31
Local Institution
Stockholm, Sweden, 141 86
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: Bristol-Myers Squibb Identifier: NCT01602367     History of Changes
Other Study ID Numbers: MB121-008
2012‐000509‐54 ( EudraCT Number )
Study First Received: May 17, 2012
Last Updated: September 23, 2015

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Body Weight
Signs and Symptoms processed this record on September 19, 2017